Abintus Bio: Funding, Investors & Team (Sep 2026)
Abintus Bio is a preclinical stage gene therapy company that engages in the field of in vivo immune cell reprogramming. The company pursues products that modulate immune cells from within their native environment to enhance patient access and patient outcomes. It focuses on the discovery and development of a portfolio of first-in-class, product candidates that are designed to directly reprogram immune cells from within their native environment using proprietary vectors and related technologies.
Abintus Bio has raised $13.7M across 1 funding round on record, the most recent an undisclosed round of $13.7M announced in Aug 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Abintus Bio Company Profile and Key Stats
Latest funding round on record: Aug 2022.
Abintus Bio Funding Rounds
Abintus Bio Founders and Leadership Team
No contact details are on record for this team yet.
Abintus Bio Funding Compared to Other Biotechnology Startups
Abintus Bio's latest round of $13.7M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Abintus Bio in Biotechnology and San Diego
Companies Similar to Abintus Bio
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Abintus Bio Funding FAQs
What does Abintus Bio do?
Abintus Bio is a preclinical stage gene therapy company that engages in the field of in vivo immune cell reprogramming. The company pursues products that modulate immune cells from within their native environment to enhance patient access and patient outcomes. It focuses on the discovery and development of a portfolio of first-in-class, product candidates that are designed to directly reprogram immune cells from within their native environment using proprietary vectors and related technologies.
How much funding has Abintus Bio raised?
Abintus Bio has raised $13.7M across 1 round on record. The most recent is an undisclosed round of $13.7M announced in Aug 2022.
When did Abintus Bio last raise funding?
Abintus Bio's most recent funding round on record is an undisclosed round of $13.7M, announced in Aug 2022.
Who founded Abintus Bio?
FundedIQ lists John Snyder (Founder) at Abintus Bio.
Where is Abintus Bio headquartered?
Abintus Bio is based in San Diego, California, United States.
How many employees does Abintus Bio have?
Abintus Bio is in the 11-50 employee band.
How does Abintus Bio's funding compare to other Biotechnology startups?
Abintus Bio's latest round of $13.7M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Abintus Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Abintus Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.